In multivariable analysis, six clinicopathologic variables were significantly associated with time to recurrence: ulceration, tumor thickness, tumor location, neurotropism (tumor growth along nerves), ...
A secondary analysis of the phase 3 KEYNOTE-716 trial finds that adjuvant Keytruda improves recurrence-free survival without increasing the risk of new primary melanoma and may reduce non-melanoma ...
Investigators sought to determine whether adjuvant pembrolizumab is associated with the risk of developing subsequent cutaneous malignant neoplasms in patients with high-risk stage II melanoma.
Hosted on MSN
Teddi Mellencamp's melanoma: Everything the reality star has said about her cancer diagnosis
After first being diagnosed with stage 2 melanoma in 2022, her cancer progressed to stage 4 in 2025 Real Housewives star Teddi Mellencamp was diagnosed with stage 2 melanoma in 2022 Since then, she ...
The ASCO 2025 meeting reinforced current melanoma treatment protocols, emphasizing practice-affirming data rather than introducing new standards. RELATIVITY-098 study confirmed anti-PD-1 monotherapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results